Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

653 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies.
Rizzieri DA, Feldman E, Dipersio JF, Gabrail N, Stock W, Strair R, Rivera VM, Albitar M, Bedrosian CL, Giles FJ. Rizzieri DA, et al. Among authors: giles fj. Clin Cancer Res. 2008 May 1;14(9):2756-62. doi: 10.1158/1078-0432.CCR-07-1372. Clin Cancer Res. 2008. PMID: 18451242 Clinical Trial.
Antiangiogenic therapy in leukemia.
Thomas DA, Giles FJ, Cortes J, Albitar M, Kantarjian HM. Thomas DA, et al. Among authors: giles fj. Acta Haematol. 2001;106(4):190-207. doi: 10.1159/000046616. Acta Haematol. 2001. PMID: 11815717 Review.
Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
Kantarjian HM, Talpaz M, O'Brien S, Smith TL, Giles FJ, Faderl S, Thomas DA, Garcia-Manero G, Issa JP, Andreeff M, Kornblau SM, Koller C, Beran M, Keating M, Rios MB, Shan J, Resta D, Capdeville R, Hayes K, Albitar M, Freireich EJ, Cortes JE. Kantarjian HM, et al. Among authors: giles fj. Clin Cancer Res. 2002 Jul;8(7):2177-87. Clin Cancer Res. 2002. PMID: 12114418 Clinical Trial.
Differences in CD33 intensity between various myeloid neoplasms.
Jilani I, Estey E, Huh Y, Joe Y, Manshouri T, Yared M, Giles F, Kantarjian H, Cortes J, Thomas D, Keating M, Freireich E, Albitar M. Jilani I, et al. Am J Clin Pathol. 2002 Oct;118(4):560-6. doi: 10.1309/1WMW-CMXX-4WN4-T55U. Am J Clin Pathol. 2002. PMID: 12375643
653 results